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INTRODUCTION
Impulse-control disorder (ICD) and compulsive repetitive 
behaviors such as hobbyism/punding and dopamine dys-
regulation syndrome (DDS) are common in Parkinson’s dis-
ease (PD). The prevalence of ICD and related behaviors in PD 
patients has been reported to be 10–20%.1-16 A recent study 
found that the 5-year cumulative incidence of ICD and relat-
ed behaviors in PD was 46%.17,18 It is important to assess ICD 
and related behaviors because these behavioral disturbances 
can lead to devastating financial problems, emerging prob-
lems with online gambling or shopping, and impaired quality 
of life in both patients and their caregivers.19 
The Questionnaire for Impulsive-Compulsive Disorders in 
Parkinson’s Disease (QUIP) has been developed for screen-
ing pathological gambling, hypersexuality, excessive buying, 
overeating, hobbyism/punding, and DDS in PD patients.8 
However, it cannot be used to assess the severity of these be-
havioral disturbances, nor monitor changes in these behav-
iors. The Questionnaire for Impulsive-Compulsive Disorders 
in Parkinson’s Disease Rating Scale (QUIP-RS) is a self-re-
ported tool for assessing the severity of ICD and related be-
haviors that uses a 5-point Likert scale based on frequency.20 
The present nationwide multicenter prospective study aimed 
to validate the Korean Version of the Questionnaire for Im-
pulsive-Compulsive Disorders in Parkinson’s Disease Rating 
Scale (K-QUIP-RS) and to determine the correlations between 
the severity of impulsive-compulsive behaviors and clinical 
features and the quality of life in the Korean PD population. 
METHODS
Study participants 
We recruited patients with PD from 27 movement-disorder 
centers at university-affiliated hospitals in Korea. Korean PD 
patients who met the diagnostic criteria of the UK Parkin-
son’s Disease Society Brain Bank21 and had been taking sta-
ble doses of antiparkinsonian medications for at least 4 weeks 
prior to their participation were included in this study. Pa-
tients were excluded when they had a diagnosis of secondary 
parkinsonism or symptoms suggesting Parkinson-plus syn-
drome (e.g., multiple system atrophy,22 progressive supra-
nuclear palsy,23 corticobasal degeneration,24 or dementia with 
Lewy bodies25), had undergone deep-brain stimulation, had 
a history of psychiatric diseases with antipsychotic or anti-
depressant medications that could secondarily affect behav-
iors, or had taken medication that can cause drug-induced 
parkinsonism. The Institutional Review Board at each par-
ticipating hospital approved this study (SMG-SNU Boramae 
Medical Center, IRB No. 16-2014-119). Informed consent 
was obtained by all subjects.
We constructed the K-QUIP-RS through forward and back-
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ward translation of the original QUIP-RS.20 After expert pan-
els had reviewed the draft of the K-QUIP-RS, it was applied 
to four Korean PD patients to confirm its validity prior to this 
study. The final version of the K-QUIP-RS is provided as sup-
plementary data.
Assessment
Clinical assessments were performed using the following 
components: the total daily levodopa equivalent dose (total 
LED) and the agonist LED from the doses of dopamine ag-
onists only,26 the Hoehn and Yahr (H&Y) stage,27 the Uni-
fied Parkinson’s Disease Rating Scale (UPDRS) parts I, II, 
and III,28 the Korean Version of the Mini Mental State Ex-
amination (K-MMSE),29 the Korean Version of the Montreal 
Cognitive Assessment (MoCA-K),30 the Korean Version of 
the Montgomery-Asberg Depression Scale (K-MADS),31 the 
Korean Version of the 39-item Parkinson’s Disease Ques-
tionnaire (K-PDQ39),32 and the Korean Version of the Rapid-
Eye-Movement Sleep-Behavior-Disorders Screening Question-
naire (K-RBDQ).33,34 The test–retest reliability was measured by 
performing K-QUIP-RS assessments twice within 10–14 days 
after the first assessment, which allowed sufficient time to 
minimize learning effects.
Statistical analysis
We used Cronbach’s α coefficient to check the internal con-
sistency of the K-QUIP-RS with a criterion of ≥0.70. The 
test–retest reliability of the K-QUIP-RS was assessed using 
the Guttman split-half coefficient. Spearman’s correlation 
analysis was used to investigate correlations of the K-QUIP-
RS score with other clinical scales. SPSS software (version 
21.0, IBM Corp., Armonk, NY, USA) was used for statistical 
analysis, with the significance cutoff set at 0.05 (two-tailed).
RESULTS
This study enrolled 136 patients (65 males) aged 66.8±9.0 
years (mean±SD) and with a PD duration of 47.3±46.8 
months. The retest evaluation was completed in 133 of these 
patients. The demographic and clinical characteristics of the 
participants finally included in the analysis are summarized 
in Table 1.
K-QUIP-RS scores in the study population
The total K-QUIP-RS score was 2.5±5.0 (range, 0 to 28), 
and the total ICD items score—comprising the summation 
score in the domains of gambling, hypersexuality, buying, 
and eating—was 1.2±2.7 (range, 0 to 16). The frequencies of 
positive responders for the gambling, hypersexuality, buying, 
and eating items were 5.9%, 9.6%, 11.8%, and 20.6%, respec-
tively. The frequency of positive responders for any of these 
Table 1. Characteristics of the 136 patients included in this study
             Variable Value
Age, years 66.8±9.0 (39–85)
Sex, male 65 (47.8)
Disease duration, months 47.3±46.8 (1–252)
Total LED, mg/day 654.8±473.4 (0–2250)
Agonist LED, mg/day 107.5±149.7 (0–825)
H&Y stage 2.1±0.7 (1–5)
UPDRS part I score 2.0±2.0 (0–8)
UPDRS part II score 7.8±6.0 (0–29)
UPDRS part III score 20.2±11.0 (0–54.5)
K-MMSE score 26.9±3.7 (4–30)
MoCA-K score 22.6±5.0 (1–30)
K-MADS score 10.3±9.6 (0–40)
K-PDQ39 summary index 33.1±28.5 (0–123)
K-RBDQ score 3.3±2.9 (0–13)
Data are mean±SD (range) or n (%) values. 
H&Y: Hoehn and Yahr, K-MADS: Korean Version of the Montgomery-
Asberg Depression Scale, K-MMSE: Korean Version of the Mini Mental 
State Examination, K-PDQ39: Korean Version of the Parkinson’s Disease 
Quality of Life-39, K-RBDQ: Korean Version of the Rapid-Eye-Move-
ment Sleep-Behavior-Disorders Screening Questionnaire, LED: levodopa 
equivalent dose, MoCA-K: Korean Version of the Montreal Cognitive 
Assessment, UPDRS: Unified Parkinson’s Disease Rating Scale.
Table 2. Distribution of the K-QUIP-RS scores in the Parkinson’s disease patients included in this study
K-QUIP-RS domain Mean±SD Median (range) n (%) for score ≥1 n (%) for score ≥ suggested cutoff *
Gambling  0.3±1.3 0 (0–12) 8 (5.9) 1 (0.7)
Hypersexuality 0.2±0.9 0 (0–7) 13 (9.6) 0 (0.0)
Buying 0.2±0.8 0 (0–5) 16 (11.8) 0 (0.0)
Eating 0.5±1.2 0 (0–8) 28 (20.6) 1 (0.7)
Hobbyism/punding 1.1±2.6 0 (0–18) 33 (24.3) 6 (4.4)
DDS 0.2±1.2 0 (0–10) 6 (4.4) NA
Summed score for ICD† 1.2±2.7 0 (0–16) 39 (28.7) 5 (3.7)
Total K-QUIP-RS score 2.5±5.0 0 (0–28) 47 (34.6) NA
*Cutoffs from the original American Version of the QUIP-RS: gambling, ≥6; hypersexuality, ≥8; buying, ≥8; eating, ≥7; hobbyism/punding, ≥7; and 
summed score for ICD, ≥10, †Summed score for ICD domains includes gambling, hypersexuality, buying, and eating.
DDS: dopamine dysregulation syndrome, ICD: impulse-control disorder, K-QUIP-RS: Korean Version of the Questionnaire for Impulsive-Compulsive 
Disorders in Parkinson’s Disease Rating Scale, NA: not available.
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four ICD domains was 28.7%. Based on a recommended 
cutoff of the total ICD items score of ≥10 for diagnosing ICD 
in PD,20 3.7% of the participants were classified as having 
ICD. The scores and frequencies in the individual domains 
and for the total K-QUIP-RS score are presented in Table 2.
Internal consistency and test–retest reliability of 
the K-QUIP-RS
Cronbach’s α coefficient for the total K-QUIP-RS was 0.846, 
and it was also ≥0.70 in each K-QUIP-RS domain. The 
scores in each domain of the K-QUIP-RS were correlated 
with the total K-QUIP-RS score (Spearman’s rank correlation 
coefficient=0.392–0.887, p<0.001 in all) (Table 3). The Gutt-
man split-half coefficient for the total K-QUIP-RS score was 
0.808, and it was also ≥0.70 for the sum of the ICD items 
and for the score in all except two ICD domains: hypersex-
uality (0.079) and DDS (0.347) (Table 3).
Correlation between the K-QUIP-RS score and 
other clinical measures
The total K-QUIP-RS score and the summed score for ICD 
items were not correlated with age, PD duration, parkinso-
nian motor severity (H&Y stage and UPDRS part III score), 
or global cognition (K-MMSE and MoCA-K scores). How-
ever, the total K-QUIP-RS score was positively correlated 
with the UPDRS part I score, specifically for depression and 
motivation items (r=0.176 and 0.239, and p=0.041 and 0.005, 
respectively), and with the UPDRS part II score (r=0.214 and 
p=0.012). Both the total K-QUIP-RS score and the summed 
scores for ICD domains were positively correlated with scores 
on the K-MADS (r=0.224 and 0.230, and p=0.009 and 0.007, 
respectively), K-RBDQ (r=0.220 and 0.216, and p=0.010 and 
0.012), and K-PDQ39 (r=0.223 and 0.171, and p=0.009 and 
0.048) (Fig. 1). The total K-QUIP-RS score was also correlated 
with the total and agonist LEDs (r=0.209 and 0.181, and p= 
0.019 and 0.043, respectively) (Fig. 1). The results obtained 
in the correlation analysis are summarized in Table 4.
DISCUSSION
This nationwide multicenter study has demonstrated that 
the K-QUIP-RS has good consistency and reliability in the 
Korean PD population. Cronbach’s α coefficient was 0.846 
for the total K-QUIP-RS and also ≥0.70 in every K-QUIP-
RS domain. The test–retest reliability was good for the total 
K-QUIP-RS and in four of the six K-QUIP-RS domains, and 
suboptimal for the hypersexuality (0.079) and DDS (0.347) 
domains (based on the Guttman split-half coefficient).
In this study population, the frequency of positive re-
sponders for any of four ICD domains in the K-QUIP-RS 
was 28.7%, and for any of all six domains was 34.6%. How-
ever, the prevalence of ICD in this study population was esti-
mated to be 3.7% when we applied the suggested cutoff.20 
This was lower than the range of reported prevalence rates of 
ICD (5–20%),1-3,5-7,9-16 and also much lower than those re-
ported for the French QUIP-RS study (12.5%) and the Mexi-
can QUIP-RS study (4.6%) with the same cutoff applied.16,35
The scores in four ICD domains in this study were also 
lower than those in the original report on an American pop-
ulation and in reports from other countries including France, 
Mexico, Germany, and Philippines.16,35-37 These discrepancies 
might be related to the low proportion of users of high-dose 
dopamine agonist in this study, because dopamine agonist 
is a strong risk factor for ICD in PD, which is dose-depen-
dent.5,17,18 In addition, our study population included patients 
who were much older at the onset of PD and included a lower 
proportion of males than the other studies, and both of these 
factors are negatively associated with the risk of ICD.1,18 In 
line with this, the inclusion of only a small number of early-
onset PD patients in our study might have contributed to the 
relatively low ICD prevalence in the study population. Previ-
ous studies found that the susceptibility to ICD was higher 
in patients with parkin or PINK1 mutations,38-41 and that the 
ICD scores of the QUIP-RS were higher in PD/ICD with par-
kin mutation than in gene-negative early-onset PD/ICD.41 
However, the genetic predisposition to develop ICD was not 
investigated in the present validation study. Moreover, the 
lower severity of ICD in the present population might have 
also been related to the tendency of Korean patients to un-
derreport their behaviors on self-reported questionnaires. 
Influences of variations in ethnic characteristics and cultural 
Table 3. Test–retest reliability of the K-QUIP-RS and coefficients for 








Gambling 0.908 0.392 <0.001
Hypersexuality 0.079 0.539 <0.001
Buying 0.863 0.551 <0.001
Eating 0.708 0.723 <0.001
Hobbyism/punding 0.830 0.820 <0.001
DDS 0.347 0.379 <0.001
Summed score for ICD 0.726 0.887 <0.001
Total K-QUIP-RS score 0.808 - -
Summed score for ICD domains includes gambling, hypersexuality, buy-
ing, and eating.
DDS: dopamine dysregulation syndrome, ICD: impulse-control disor-
der, K-QUIP-RS: Korean Version of the Questionnaire for Impulsive-
Compulsive Disorders in Parkinson’s Disease Rating Scale, rS: Spear-
man’s rank correlation coefficient.
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backgrounds might result in the optimal cutoff for ICD of 
the QUIP-RS differing between populations. In a German 
validation study, the optimal cutoff was 3 points lower than 
that in the original QUIP-RS developed in the US.36 Further 
investigations of the K-QUIP-RS are deemed necessary to 
confirm whether the suggested cutoff from the original ver-
sion20 is reliable in the Korean PD population. 
The low test–retest reliability found for the hypersexuality 
domain of the K-QUIP-RS in this study might be explained 
by the characteristics of Confucian culture in Korea. Con-
fucian culture emphasizes concealing sexual desire or being 
ashamed to be revealed as having abnormal sexual behav-
ior,42 which could contribute to the tendency of Korean PD 
patients to underreport hypersexuality more than other ICD 
behaviors, and could also result in greater variations in their 
reported values during repeated screening. Another possi-
bility is that the questionnaire for hypersexuality is not suf-
ficiently sensitive to detect this type of ICD in Korean PD pa-
tients. An intriguing finding of this study was that the most-
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Fig. 1. Correlations between the total score on the K-QUIP-RS and other clinical measures. (A) total LED (R2=0.078, p=0.019) and scores on the (B) 
K-MADS (R2=0.033, p=0.009), (C) K-PDQ39 SI (R2=0.052, p=0.009), and (D) K-RBDQ (R2=0.057, p=0.010). K-MADS: Korean Version of the Mont-
gomery-Asberg Depression Scale, K-PDQ39: Korean Version of the Parkinson’s Disease Questionnaire-39, K-QUIP-RS: Korean Version of the Ques-
tionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease Rating Scale, K-RBDQ: Korean Version of the Rapid-Eye-Movement Sleep-Be-
havior-Disorders Screening Questionnaire, LED: levodopa equivalent dose, SI: summary index.
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single-center study of screening ICD using the QUIP8 and 
a multicenter study using the mMIDI (modified Minnesota 
Impulsive Disorders Interview)43 in the Korean PD popula-
tion found that hypersexuality was the most-common ICD.6,44 
In contrast to these two previous studies, we strictly excluded 
subjects who had previously received or were currently re-
ceiving treatment for psychiatric diseases; this might have 
contributed to the inconsistent finding of ICD being less 
devastating or problematic in our study than in those previ-
ous ones. However, the low reliability in the hypersexuality 
domain of the K-QUIP-R suggested that hypersexuality was 
underestimated, for the reasons mentioned above. On the oth-
er hand, the prevailing ICD in PD has varied between differ-
ent countries, being hypersexuality in Finland (22.8%), Brazil 
(11.8%), India (11.4%), and Denmark (9%), eating in Norway 
(10%), Malaysia (8.7%), and Mexico (8.6%), buying in the US 
and Canada (5.7%), and gambling in Japan (6.5%) and the US 
and Canada (5%).1,5,9,11-16
We found a low test–retest reliability for DDS (r=0.347) in 
this study. Previous studies of the QUIP-RS in other popula-
tions have also found low reliability in the DDS domain, 
with r values of 0.58 and 0.61 in French and German popula-
tions, respectively.35,36 DDS is usually accompanied by mood 
swings such as hypomanic, manic, or cyclothymic mood in 
the medication-on state, and withdrawal dysthymia or de-
pression when dopaminergic medications are reduced.45-47 
These fluctuating symptoms might affect the reliability of 
using the QUIP-RS to detect DDS. PD patients with DDS 
take more dopaminergic medications to alleviate the medi-
cation-off mood states and motor symptoms, but patients 
with DDS experience smaller improvements than PD patients 
without DDS when treated with the same medication.48 This 
might result in them underreporting their condition in such 
a self-reported questionnaire, or discriminating DDS from 
true dopaminergic medication use might be difficult when pa-
tients suffer dopa-responsive nonmotor medication-off symp-
toms based on the self-reports. On the other hand, the ICD se-
verity was found to be lower when assessed in a self-reported 
questionnaire than in caregiver reports, and the assessment of 
ICD can be improved by using a clinician-rated scale.49,50 
The total K-QUIP-RS score and the ICD-item summed 
scores were not related to the parkinsonian motor severity 
or global cognition, but they were correlated with depression, 
quality of life, and rapid-eye-movement sleep-behavior dis-
orders (RBD). Other than dopaminergic drugs, the previously 
reported risk factors for ICD include being younger at PD 
onset, male,1,5,16-18 and having depression, alexithymia, anxi-
ety, aggression, impulsivity, or obsessive-compulsiveness.51-54 
Previous findings for the relationship between RBD and ICD 
in PD have been controversial, with some studies showing an 
association and others finding no significant relationship.55-57 
According to a recent large population-based epidemiological 
study of RBD, the risk of RBD development is associated 
with male sex, alcohol use, smoking, antidepressant use for 
depression, and psychological distress,58 which are also shared 
risk factors for ICD.13,51,59 Our study supports the presence of 
associations between ICD and depression and RBD. How-
ever, since this study had a cross-sectional design, future lon-
gitudinal studies are needed that consider other risk factors 
for ICD including the history of smoking, alcohol use, and 
drug- and substance-use disorders.
This multicenter validation study has shown that the K-
Table 4. Coefficients for the correlations between the K-QUIP-RS 







Disease duration 0.044 0.077
Total LED 0.134 0.209*
Agonist LED 0.117 0.181*
H&Y stage 0.091 0.121
UPDRS part I 0.091 0.200*
Intellectual impairment 0.114 0.133
Thought disorder 0.078 0.105
Depression 0.026 0.176*
Motivation/initiative 0.152 0.239†
UPDRS part II 0.114 0.214*
UPDRS part III 0.058 0.084
K-MMSE score -0.133 -0.132
MoCA-K score -0.028 -0.044
K-MADS score 0.230** 0.224†
K-PDQ39 summary index 0.171* 0.223†
Mobility 0.110 0.160
Activities of daily living 0.139 0.171*
Emotional well-being 0.145 0.213*
Stigma 0.040 0.122
Social support 0.170* 0.219*
Cognition 0.259* 0.273†
Communication 0.238** 0.264†
Bodily discomfort 0.231** 0.302†
K-RBDQ score 0.216* 0.220*
Summed score for ICD domains includes gambling, hypersexuality, 
buying, and eating. Spearman’s rank correlation test: *p<0.05, †p<0.01. 
H&Y: Hoehn and Yahr, ICD: impulse-control disorder, K-MADS: Korean 
Version of the Montgomery-Asberg Depression Scale, K-MMSE: Kore-
an Version of the Mini Mental State Examination, K-PDQ39: Korean 
Version of the Parkinson’s Disease Quality of Life-39, K-QUIP-RS: Ko-
rean Version of the Questionnaire for Impulsive-Compulsive Disorders 
in Parkinson’s Disease Rating Scale, K-RBDQ: Korean Version of the 
Rapid-Eye-Movement Sleep-Behavior-Disorders Screening Question-
naire, LED: levodopa equivalent dose, UPDRS: Unified Parkinson’s Dis-
ease Rating Scale.
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QUIP-RS is a useful screening tool with good consistency 
and reliability for assessing ICD and related behavioral dis-
turbances in the Korean PD population. However, further 
validation studies are needed to determine the optimal cut-
off score of the K-QUIP-RS, how to implement a confirma-
tive interview between the physician and both patients and 
caregivers, and how best to examine patients when ascertain-
ing the presence of ICD, particularly for assessing hypersex-
uality and DDS.
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